(Q37882596)

24 August 2017

1 reference

title

Milestones in Parkinson's disease therapeutics (English)

1 reference

24 August 2017

1 reference

4

Werner Poewe

1 reference

24 August 2017

1

Olivier Rascol

1 reference

24 August 2017

2

Andres Lozano

1 reference

24 August 2017

3

Matthew Stern

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

26

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

1072-1082

1 reference

Treatment interventions for Parkinson's disease: an evidence based assessment

24 August 2017

cites work

1 reference

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations

21 January 2018

1 reference

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

21 January 2018

1 reference

Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities

21 January 2018

1 reference

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

21 January 2018

1 reference

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

21 January 2018

1 reference

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

21 January 2018

1 reference

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

21 January 2018

1 reference

Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.

21 January 2018

1 reference

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

21 January 2018

1 reference

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

21 January 2018

1 reference

Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease

21 January 2018

1 reference

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study

21 January 2018

1 reference

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

21 January 2018

1 reference

SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS

21 January 2018

1 reference

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

21 January 2018

1 reference

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

21 January 2018

1 reference

Long-term treatment of Parkinson's disease with bromocriptine

21 January 2018

1 reference

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up

21 January 2018

1 reference

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

21 January 2018

1 reference

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

21 January 2018

1 reference

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

21 January 2018

1 reference

Dopaminagonists and fibrotic valvular heart disease: further considerations

21 January 2018

1 reference

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

21 January 2018

1 reference

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

A 32-year-old man with progressive spasticity and parkinsonism

21 January 2018

1 reference

Increased daytime sleepiness in Parkinson's disease: a questionnaire survey

21 January 2018

1 reference

Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers.

21 January 2018

1 reference

Sleepiness in Parkinson's disease: a controlled study.

21 January 2018

1 reference

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

21 January 2018

1 reference

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

21 January 2018

1 reference

Impulsive and compulsive behaviors in Parkinson's disease.

21 January 2018

1 reference

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

21 January 2018

1 reference

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

21 January 2018

1 reference

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

21 January 2018

1 reference

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

21 January 2018

1 reference

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

21 January 2018

1 reference

Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

The delayed-start study in Parkinson disease: can't satisfy everyone

21 January 2018

1 reference

Neuroprotection trials in Parkinson's disease: systematic review

21 January 2018

1 reference

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

21 January 2018

1 reference

Genetic animal models of Parkinson's disease

21 January 2018

1 reference

Biochemistry of Parkinson's disease 28 years later: a critical review

21 January 2018

1 reference

Nondopaminergic mechanisms in levodopa-induced dyskinesia

21 January 2018

1 reference

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy

21 January 2018

1 reference

Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice

21 January 2018

1 reference

Non-dopaminergic treatments in development for Parkinson's disease

21 January 2018

1 reference

Combined treatment of parkinsonism with L-dopa and amantadine

21 January 2018

1 reference

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

21 January 2018

1 reference

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

21 January 2018

1 reference

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

21 January 2018

1 reference

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

21 January 2018

1 reference

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

21 January 2018

1 reference

Invited Article: Nervous system pathology in sporadic Parkinson disease

21 January 2018

1 reference

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.

21 January 2018

1 reference

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

21 January 2018

1 reference

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

The Effect of Thalamotomy on the Progress of Unilateral Parkinson's Disease

21 January 2018

1 reference

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease.

21 January 2018

1 reference

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

21 January 2018

1 reference

Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate

21 January 2018

1 reference

Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys

21 January 2018

1 reference

Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease

21 January 2018

1 reference

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

21 January 2018

1 reference

A randomized trial of deep-brain stimulation for Parkinson's disease.

21 January 2018

1 reference

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease

21 January 2018

1 reference

Selegiline and mortality in Parkinson's disease

21 January 2018

1 reference

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

21 January 2018

1 reference

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

21 January 2018

1 reference

Gene therapy: a viable therapeutic strategy for Parkinson's disease?

21 January 2018

1 reference

Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders.

21 January 2018

1 reference

Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus

21 January 2018

1 reference

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.23714

1 reference

24 August 2017

1 reference